vimarsana.com
Home
Live Updates
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Ta
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Ta
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...
Related Keywords
Mike Beyer ,
Jennifer Porcelli ,
Clinical Development ,
Exchange Commission ,
Sam Brown Inc ,
Prnewswire Biohaven Ltd ,
Biohaven Vice President ,
Clinical Development Lead ,
Drug Designation ,
Fast Track ,
Orphan Drug Designation ,
Kenneth Hobby ,
Motor Function Measure ,
Spinal Muscular Atrophy ,
Private Securities Litigation Reform Act ,
Financial Condition ,
Biohaven Ltd ,